Persist AI and Nivagen to Develop AI-Driven Manufacturing Process for LAI Drugs
The collaboration aims to simplify and accelerate the development and approval of LAI drugs, which can provide sustained and controlled release of drugs over weeks or months, improving patient adherence and outcomes.
Nivagen | 13/08/2024 | By Aishwarya | 586
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy